Enlicitide

DB22580ApprovedInvestigationalSmall moleculePCSK9 Inhibitor

Enlicitide is a macrocyclic peptide inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds low-density lipoprotein receptors (LDLR) on the surface of hepatocytes and promotes their degradation within... Unlike the monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab), enlicitide is administered orally as a once-daily tablet.

Mechanism: Pharmacologically active on Proprotein convertase subtilisin/kexin type 9
Curator reviewed

Resolves to

Compound

UNIIR7EZ772VG2CAS2407527-14-2

Clinical / RWD

RxNorm2747751

Targets

Q8NBP7PCSK9

What you can answer from here — as of August 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Enlicitide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account